Loading
A phase 3 trial testing QL1706 in non-small-cell lung cancer, now recruiting.
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection is a phase 3 interventional study registered as NCT05487391, led by Qilu Pharmaceutical, and recruiting on the registry. Official title: QL1706 Combined With Platinum-based Chemotherapy Versus Placebo Combined With Platinum-based Chemotherapy as Adjuvant Therapy for Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection: a Randomised, Double-blind, Multicenter Phase III Clinical Study. Planned enrolment is 632 participants (estimated). The study started in 2022-12-08 and primary completion is expected in 2027-08-31. No results have been posted on ClinicalTrials.gov.
Shares QL1706, Qilu Pharmaceutical, Non-small-cell lung cancer.
Shares QL1706, Qilu Pharmaceutical.
Shares QL1706, Qilu Pharmaceutical.
Shares QL1706, Qilu Pharmaceutical.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Qilu Pharmaceutical, Resectable stage I to III non-small-cell lung cancer.